Penumbra, Inc.

Day range

$323.88 – $325.33

Open

$324.96

Prev close

$324.96

Volume

360.03K

Market cap

$12.8B

Shares out

39.39M

P/E

79.71

P/S

8.51

P/B

8.36

P/FCF

59.28

ROE

10.5%

ROA

8.1%

Debt/Equity

0.01

Div yield

0.00%

As of Oct 22, 2026

• Shareholder meetingsJun 22, 2026

  Penumbra, Inc. held its Annual Meeting of Stockholders on June 18, 2026. At the Annual Meeting, Penumbra's stockholders voted on the following three proposals: (1) Election of Class II Directors with results showing Arani Bose, M.D., Bridget O'Rourke, and Surbhi Sarna were elected; (2) Ratification of Selection of Independent Registered Public Accounting Firm (PricewaterhouseCoopers LLP) with 29,208,244 votes for; and (3) Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers with 24,113,038 votes for.

• Deal agreementsMay 7, 2026

  A proposal to adopt the Agreement and Plan of Merger (the 'Merger Agreement'), dated January 14, 2026, by and among the Company, Boston Scientific Corporation, a Delaware corporation ('Parent'), and Pinehurst Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ('Merger Sub'), pursuant to which Merger Sub will merge with and into the Company (the 'Merger'), with the Company surviving as a wholly owned subsidiary of Parent, was approved.

• Earnings and performanceJan 15, 2026

  On January 15, 2026, the Company issued a press release announcing certain preliminary financial results for the fiscal quarter and year ended December 31, 2025. The Company's audited financial statements for the year ended December 31, 2025 are not yet available. Accordingly, these preliminary financial results are an estimate and subject to the completion of the Company's financial closing and other procedures and finalization of the Company's consolidated financial statements.

• Executive leadershipAug 27, 2025

  On August 22, 2025, the Board of Directors (the "Board") of Penumbra, Inc. (the "Company") appointed Shruthi Narayan as President of the Company, effective September 1, 2025. Ms. Narayan, 41, joined Penumbra in 2013, serving as a product manager starting off on the stroke franchise, then transitioning to help build the peripheral vascular division and commercialize the Company's vascular portfolio of embolization and thrombectomy products globally.

• Governance documentsMay 30, 2025

  On May 28, 2025, Penumbra, Inc. filed an Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware. The Amended and Restated Charter has two effects: (i) to phase in the declassification of Penumbra's Board of Directors over a three-year period to allow the Company's stockholders to vote on the election of directors generally on an annual basis, rather than on a staggered basis (the 'Declassification Amendment'), and (ii) to replace the provisions that require the affirmative vote of sixty-six and two-thirds percent (66 2/3%) of Penumbra's voting stock with a majority voting standard for such actions (the 'Supermajority Amendment').

• LNTHLantheus Holdings, Inc-0.30%
• ITGRInteger Holdings Corporation-0.02%

Days to cover

4.8

Short interest

2.25M

Avg volume

472.61K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• IART vs. PEN: Which Stock Is the Better Value Option?
  positiveZacks Investment Research· Oct 1, 2026
• IART or PEN: Which Is the Better Value Stock Right Now?
  positiveZacks Investment Research· Sep 29, 2026
• Reasons to Retain Penumbra Stock in Your Portfolio for Now
  neutralZacks Investment Research· Sep 16, 2026
• Incuvate Files Patent Infringement Lawsuit Against Penumbra
  negativeGlobeNewswire Inc.· Aug 25, 2026
• GuideAI Health Appoints Renowned Interventional Radiologist Dr. James Benenati to Advisory Board Following FDA 510(k) Clearance of VAOT
  neutralGlobeNewswire Inc.· Jul 6, 2026